SCM
BIOA

Stonepine Capital Management’s BioAge Labs BIOA Stock Holding History

Stonepine Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$875K Buy
50,000
+5,000
+11% +$96.3K 0.35% 43
2025
Q4 		$595K Sell
45,000
-143,571
-76% -$1.27M 0.43% 47
2025
Q3 		$1.11M Buy
188,571
+37,486
+25% +$176K 0.9% 24
2025
Q2 		$624K Buy
151,085
+101,085
+202% +$407K 0.61% 37
2025
Q1 		$188K Buy
+50,000
New +$231K 0.18% 50

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Stonepine Capital Management's BIOA Position: Q1 2026 in Review

Stonepine Capital Management increased its BioAge Labs (BIOA) stake by 11% in Q1 2026, buying an estimated $96.3K and bringing the position to 50,000 shares worth $875K. The position accounts for 0.35% of the portfolio, ranked #43.

Stonepine Capital Management first reported a position in BIOA in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.11M in Q3 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Stonepine Capital Management held 50,000 shares of BioAge Labs worth $875K as of Q1 2026.
  • Stonepine Capital Management bought 5,000 BioAge Labs shares in Q1 2026, an estimated $96.3K.
  • BioAge Labs made up 0.35% of Stonepine Capital Management's portfolio in Q1 2026, its #43 holding.
  • Stonepine Capital Management first reported a position in BioAge Labs in Q1 2025 and has held it in 5 quarters since.
  • Stonepine Capital Management's BioAge Labs position peaked at $1.11M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.